Description:
Effectiveness of conventional IgG antibodies is often limited by tissue penetration, particularly in solid tumors and across the blood–brain barrier (BBB). VHHs and heavy-chain-only antibodies (HCAbs) represent a differentiated modality, offering small size, high stability, and longer CDR3 regions that enable access to cryptic or hard-to-reach epitopes.
In this webinar, we will present Biocytogen’s RenNano® platform for the discovery of fully human HCAbs. Built to deliver diverse, high-affinity HCAb binders, RenNano (RN) supports a broad range of next-generation therapeutic strategies.
We will highlight how RN molecules are enabling innovative approaches, including BBB shuttle design, bispecific and multispecific antibodies, ADCs, and targeted delivery for in vivo CAR-T therapies. Selected case studies will provide insights into their functional performance and therapeutic potential.
Join us to explore how these differentiated antibody formats are expanding the boundaries of antibody-based therapeutics.
Speaker：
W. Frank An, Ph.D
Vice President Institute for Biologics
Biocytogen Boston Corp..
Dr. An is the Vice President of the Institute of Biologics, which is Biocytogen’s antibody discovery division. Frank earned his Ph.D. in Cellular and Molecular Biology from Brandeis University, followed by a postdoc fellowship in Immunology at Dana Farber Cancer Institute and Harvard Medical School. With over twenty years of experience in drug discovery across industry and academia, his key responsibilities include overseeing Biocytogen’s internal and external collaborative antibody discovery programs, covering oncology, autoimmune disorders, rare diseases, and more, and including those that have reached PCC, nonclinical studies, IND, and clinical trial stages. He is also in charge of portfolio strategies, target inception and product profile conceptualization, as well as overall project management and implementation.
